<DOC>
	<DOCNO>NCT00736814</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know combination chemotherapy regimen effective treat non-small cell lung cancer . PURPOSE : This randomized phase II trial compare different combination chemotherapy regimens see well work first-line therapy treat patient stage IIIB stage IV non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>First-Line Combination Chemotherapy Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To assess treatment outcome adjuvant chemotherapy base ERCC1 RRM1 mRNA level patient stage IIIB IV non-small cell lung cancer . OUTLINE : Patients randomize 1 2 treatment arm . RNA isolate pretreatment biopsy sample analyze reverse transcriptase-PCR ( RT-PCR ) assay determine ERCC1 RRM1 mRNA expression . - Arm I : Patients receive standard chemotherapy comprise docetaxel IV carboplatin IV day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients treat accord ERCC1 RRM1 mRNA expression level determine RT-PCR . - Genotype A1 ( high ERCC1 high RRM1 mRNA level ) : Patients receive non-platinum doublet chemotherapy comprise docetaxel vinorelbine ditartrate IV day 1 15 . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity . - Genotype A2 ( high ERCC1 low RRM1 mRNA level ) : Patients receive non-platinum doublet chemotherapy comprise gemcitabine hydrochloride IV vinorelbine ditartrate IV day 1 8 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Genotype B1 ( low ERCC1 high RRM1 mRNA level ) : Patients receive platinum doublet chemotherapy comprise docetaxel IV carboplatin IV day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Genotype B2 ( low ERCC1 low RRM1 mRNA level ) : Patients receive platinum doublet chemotherapy comprise gemcitabine hydrochloride IV day 1 8 carboplatin IV day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove radiologically clinically suspect stage IIIB ( malignant pleural effusion ) IV nonsmall cell lung cancer Unresectable disease At least 1 measurable lesion ( &gt; 10 mm spiral CT scan &gt; 20 mm conventional CT scan ) No symptomatic untreated brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 12 week ANC ≥ 1,500/mm³ Hemoglobin &gt; 9.0 g/dL Platelet count ≥ 100,000/mm³ AST ALT &lt; 2 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 mg/dL Creatinine &lt; 1.5 time ULN Not pregnant nursing No serious uncontrolled systemic intercurrent illness , include follow : Acute myocardial infarction Uncontrolled arrhythmia Uncontrolled heart failure Sepsis Poorly control diabetes No malignancy within last 5 year , except carcinoma situ cervix nonmelanomatous carcinoma skin PRIOR CONCURRENT THERAPY : At least 3 week since prior radiotherapy , include cranial irradiation At least 3 week since prior major surgery No prior systemic chemotherapy except adjuvant chemotherapy provide complete 12 month ago</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>